• Icon International Neuroendocrine Cancer Alliance

  • Mail: post@incalliance.org

Tag: PRRT

Unicorn Foundation New Zealand, PRRT, NET patients
Great news for NET cancer community in New Zealand

Unicorn Foundation New Zeleand happily announced on 21 November 2017 that they got the result from the Consumer Submission which was made earlier in August to Pharmac, the New Zealand government agency that decides which pharmaceuticals to publicly fund in New Zealand. The Cancer Treatments Sub-committee have recommended that PRRT be funded for patients with…

Read More
SiobhanConroy, Unicorn Foundation New Zealand
Unicorn Foundation New Zealand campaigns for government funding of PRRT for NET patients

Unicorn Foundation New Zealand and eight more cancer local organizations presented a manifesto to the Minister of Health, politicians and their health advisors in a campaign to encourage all political parties to work with the NGOS to help Kiwis receive improved cancer care, funding and access to treatment no matter where one lives in New…

Read More
CNETS India
CNETS India informs Alpha PRRT is now available for NET patients in India

CNETS India team is happy to share that two nuclear medicine centres in India have started Alpha PRRT for NET patients.  World over, many clinical trials have established the benefit of PRRT for metastatic NETs. Alpha PRRT uses the more powerful alpha particle emitting agents, Actinium 225 or Bismuth 213, in place of Lutetium 177…

Read More
ron1 web
INCA MEETING FEATURES CFCF RESEARCHER: FOCUS ON PRRT

 

Blog post by Ron Hollander.

The International Neuroendocrine Cancer Alliance (INCA) held its annual  Summit and Member meeting in Oxford, England. The assembled representatives from NET groups in 18 nations focused on ways to spread awareness, assist NET groups, and support research for NET patients worldwide. 

INCA summit Oxford
(L-R) INCA Secretary Jo Grey (UK) – Association for Multiple Endocrine Neoplasia Disorders (AMEND); CFCF Funded Researcher Tim Meyer, MD, PhD – UCL Cancer Institute, University College London; INCA President Teodora Kolarova (Bulgaria) – APOZ & Friends; Ron Hollander – CFCF Executive Director; Josh Mailman – President of NorCal CarciNET Community; Yoshiyuki Majima (Japan) – PanCan

Read More
bill1 web
Good news for NET Cancer

 

Blog post by Bill Claxton.

Good news from Vienna, ECC 2015, the European Cancer Congress,
announced by Philippe Ruszniewski, MD, head of gastroenterology and pancreatology at Beaujon Hospital, in Clichy, France.

“Treatment with the novel peptide receptor radionuclide therapy (PRRT) Lutathera significantly increased progression-free survival (PFS) over octreotide LAR (Sandostatin) in patients with advanced midgut neuroendocrine tumors (NETs), according to findings from the phase III NETTER-1 trial presented at the 2015 European Cancer Congress.”
Medical abstract is here (www.europeancancercongress) and a press release is here (www.onclive.com).

 

Read More
Copyright © 2015 International Neuroendocrine Cancer Alliance. All right reserved.
Make a Donation
Paybal button